化疗对于淋巴瘤患者凝血状态的影响及临床价值

徐杰; 史阳阳; 孙凯

doi:10.13201/j.issn.1004-2806.2021.06.002

化疗对于淋巴瘤患者凝血状态的影响及临床价值

- 南京医科大学第一附属医院急诊科(南京, 210000)
基金项目:
国家自然科学基金(No:81871544)

江苏省科技厅基础研究计划(自然科学基金)(No:BK20181493)

详细信息

通讯作者: 孙凯,E-mail:sunkai@njmu.edu.cn

中图分类号: R733.4

收稿日期: 2021-01-29

Effect of chemotherapy on coagulation state and its clinical value in patients with lymphoma

- Emergency Department, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210000, China

More Information

Corresponding author: SUN Kai, E-mail: sunkai@njmu.edu.cn

Received Date: 29 January 2021

摘要

摘要: 目的:探讨淋巴瘤患者化疗过程中凝血状态的变化及临床价值。方法:①收集2019年8月—2020年4月接受化疗的69例淋巴瘤患者初诊时的临床资料作为试验组,收集同期69例健康体检的患者资料作为对照组。比较2组患者凝血功能指标,血小板计数(PLT)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(Fib)、凝血酶时间(TT)、D-二聚体(DD)的指标水平,分析试验组与对照组指标差异。②依据淋巴瘤的分期、分组、分型及ECOG评分对凝血指标进行相关性分析,探讨是否存在关联性。③采集淋巴瘤患者3次化疗前后的凝血指标,探讨化疗前后凝血功能的变化。④收集患者3次化疗前的白细胞计数(WBC)、血红蛋白(HGB)、PLT、体重指数(BMI),总结Khorana评分,评估化疗进程中静脉血栓形成风险(VTE)。结果:①试验组相较于对照组PLT、PT、Fib及DD明显升高,差异有统计学意义(P<0.05)。②不同ECOG评分间DD分布存在明显差异,且DD与ECOG评分呈正相关。不同预后患者间初诊结果差异无统计学意义(P>0.05)。③前2次化疗后PLT均较化疗前明显降低。初次化疗后患者存在明显凝血功能异常,后逐渐恢复,但DD仍持续维持较高水平。④随着化疗次数的增加,Khorana评分为高风险患者比例逐渐上升。结论:淋巴瘤患者存在明显凝血功能异常,与化疗进程显著相关。在化疗过程中应密切监测凝血指标,及时发现患者凝血功能异常,并早期干预。
- 淋巴瘤 /
- 高凝状态 /
- 血小板降低 /
- 治疗
Abstract: Objective: To investigate the changes of coagulation state and its clinical value in patients with lymphoma during chemotherapy.Methods:①Clinical data of 69 lymphoma patients receiving chemotherapy in our hospital from August 2019 to April 2020 were collected at the time of initial diagnosis as the observation group, and data of 69 patients receiving physical examination in our hospital during the same period were collected as the control group. Thrombin function indicators such as platelet count(PLT), prothrombin time(PT), partial thrombin activation time(APTT), fibrinogen(Fib), thrombin time(TT) and D-dimer(DD) were compared between the two groups, and the differences between the observation group and the control group were analyzed.②Correlation analysis was conducted on coagulation indicators according to the stage, grouping, typing and ECOG score of lymphoma to explore whether there was any correlation.③Coagulation indexes of lymphoma patients before and after 3 rounds of chemotherapy were collected to investigate the changes of coagulation function before and after chemotherapy.④White blood cell count(WBC), hemoglobin(HGB), PLT and body mass index(BMI) of patients before 3 rounds of chemotherapy were collected, and Khorana score was summarized to evaluate the risk of venous thrombosis(VTE) during chemotherapy.Results:①PLT, PT, Fib and DD in the lymphoma group were significantly increased compared with those in the control group, and the difference was statistically significant(P<0.05).②DD distribution was significantly different among different ECOG scores, and DD was positively correlated with ECOG scores. There was no significant difference in initial diagnosis among patients with different prognosis(P>0.05).③PLT after the first two chemotherapy treatments was significantly lower than that before chemotherapy. After the initial chemotherapy, the patients had obvious coagulation dysfunction and gradually recovered, but DD was still maintained at a high level.④With the increase of the number of chemotherapy, the proportion of patients with Khorana score as high-risk gradually increased.Conclusion: There were significant coagulation abnormalities in lymphoma patients, which were significantly correlated with the course of chemotherapy. Thrombin indexes should be closely monitored during chemotherapy to detect abnormal clotting function of patients in time and intervene early.
- lymphoma /
- hypercoagulable state /
- thrombopenia /
- therapy

HTML全文

参考文献(14)

[1]	Nishimura K,Ota R,Mikajiri Y,et al.Useful laboratory markers for the diagnosis of bone marrow involvement by malignant lymphoma[J].Int J Lab Hematol,2018,40(1):34-40.
[2]	Hernández-Boluda JC,Cervantes F,Alvarez A,et al.Non-Hodgkin's lymphoma following untreated essential thrombocythemia[J].Leuk Lymphoma,2000,36(3-4):421-423.
[3]	Demeter J,Istenes I,Fodor A,et al.Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia(CIT)in a patient with mantle cell lymphoma[J].Pathol Oncol Res,2011,17(1):141-143.
[4]	Kuter DJ.Managing thrombocytopenia associated with cancer chemotherapy[J].Oncology(Williston Park),2015,29(4):282-294.
[5]	范金波,彭娟,曹涛,等.贮存式自身输血在血液病化疗患者中的临床应用[J].临床血液学杂志,2015,28(4):312-314.
[6]	Al-Samkari H,Parnes AD,Goodarzi K,et al.A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies[J].Haematologica,2020.
[7]	Hohaus S,Bartolomei F,Cuccaro A,et al.Venous Thromboembolism in Lymphoma:Risk Stratification and Antithrombotic Prophylaxis[J].Cancers(Basel),2020,12(5):1291.
[8]	Ikezoe T.Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies[J].Int J Hematol,2021,113(1):34-44.
[9]	Colombo R,Gallipoli P,Castelli R.Thrombosis and hemostatic abnormalities in hematological malignancies[J].Clin Lymphoma Myeloma Leuk,2014,14(6):441-450.
[10]	Harada-Shirado K,Wang X,Mori H,et al.Circulating intranuclear proteins may play a role in development of disseminated intravascular coagulation in individuals with acute leukemia[J].Int J Hematol,2020,111(3):378-387.
[11]	Qdaisat A,Soud RA,Wu CC,et al.Poor performance of D-dimer in excluding venous thromboembolism among patients with lymphoma and leukemia[J].Haematologica,2019,104(6):e265-e268.
[12]	Mukai M,Oka T.Mechanism and management of cancer-associated thrombosis[J].J Cardiol,2018,72(2):89-93.
[13]	Dharmavaram G,Cao S,Sundaram S,et al.Aggressive lymphoma subtype is a risk factor for venous thrombosis.Development of lymphoma-specific venous thrombosis prediction models[J].Am J Hematol,2020,95(8):918-926.
[14]	Santi RM,Ceccarelli M,Bernocco E,et al.Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas.A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi(FIL)[J].Thromb Haemost,2017,27.